NEWS

Israel’s Largest Health VC Boosts Fund to $750 Million on Virus

July 22, 2020

Israel’s largest venture capital investor in life sciences, AMoon, boosted the size of its biggest fund to $750 million after demand for new health-care technology rose during the coronavirus pandemic.

Read More

Israeli healthtech VC aMoon Velocity invests $6 million in Nectin Therapeutics

July 15, 2020

Israel’s largest healthtech venture fund, aMoon, announced an investment of $6 million in Nectin Therapeutics Ltd. via its early-stage fund, aMoon Velocity.

Read More

Israel Bolsters Antibody Tests as Second Virus Wave Threatens

July 3, 2020

Israel is fortifying its national survey of exposure to the coronavirus as a second wave of infections threatens to plunge the country back into lockdown.

Read More

‘Covid Put Everything On Steroids,’ Says Prominent Healthtech Investor

June 30, 2020

When VC aMoon was established in 2017, “the premise was to invest heavily in the convergence of technology and biology, healthcare and data,” says Dr. Yair Schindel, its Managing Partner.

Read More

NIH Partners with Israeli Startup to Generate Synthetic COVID-19 Data

June 18, 2020

Through a new partnership, the National Institutes of Health will harness Israeli startup MDClone’s platform to generate computationally-derived synthetic data directly from clinical health data aggregated across the U.S., to underpin and advance research in the fight against COVID-19.

Read More

Curesponse Secures $6M Series A for Breakthrough Precision Medicine

June 5, 2020

Curesponse, a cancer precision medicine company, has raised $6M from investors including NCL Technology Ventures (UK) and aMoon (Israel) for scaling clinical trials and international expansion to the UK.

Read More

Zebra Medical Vision Secures its 5th FDA Clearance, Making Its Vertebral Compression Fractures AI Solution Available in the U.S.

May 18, 2020

Zebra Medical Vision, the deep-learning medical imaging analytics company, announces today its fifth FDA 510(k) clearance for its Vertebral Compression Fractures (VCF) product.

Read More

Ayala Pharmaceuticals Announces Pricing of Initial Public Offering

May 7, 2020

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced the pricing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.

Read More

Herd Immunity, or Big 2nd Wave? Israel Antibody Testing Hopes to Find Out

May 5, 2020

Yair Schindel, aMoon Managing Partner and a member of Israel’s health ministry task force on COVID-19, spoke to the The New York Times about the pandemic and Israel’s latest initiative to conduct nationwide serological testing on 100,000 citizens. Yair outlined the two likely scenarios Israel might find out as a result of the antibody testing.

Read More

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology

April 29, 2020

resTORbio, Inc. (Nasdaq: TORC) and Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications.

Read More

Nobio gets FDA approval for anti-bacterial dental fillings

August 5, 2019

TEL AVIV (Reuters) – Israel’s Nobio Ltd said on Monday it received approval from the U.S. Food and Drug Administration to market its anti-bacterial composite designed to remain in the teeth for decades.

Read More

Can This Ancient Greek Medicine Cure Humanity?

July 26, 2019

There’s fresh interest in a fabled shrub on the Aegean island of Chios.

Read More

Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax

July 17, 2019

Based in Jerusalem, Nasdaq-listed BiondVax develops a universal flu vaccine, currently in advanced clinical trials

Read More

First Participant Enrolled in Second Cohort of BiondVax’s Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial

July 8, 2019

BiondVax’s M-001 universal flu vaccine candidate is designed to improve upon currently marketed strain-specific vaccines in several ways.

Read More

ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration

July 8, 2019

Enabling Genomically Defined Treatments for Underserved Cancers

Read More

AI triage solution for brain bleeds gains FDA clearance

June 17, 2019

Zebra Medical Vision announced Monday, June 17, that its AI solution for intracranial hemorrhage (ICH) alerts has gained FDA approval.

Read More

CartiHeal Enrolls the 200th Patient in Its Pivotal Clinical Study in San Diego, CA

June 12, 2019

CartiHeal is the developer of the Agili-C™ implant for treating cartilage and osteochondral defects in traumatic and osteoarthritic joints,

Read More

Ayala Pharmaceuticals Raises $30 Million

May 29, 2019

The Israel-based company intends to use the new round of funding to advance the clinical development of its anti-cancer product

Read More

FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device

May 28, 2019

Clinical Data Show 66.7% Pain Relief Response Within Two Hours

Read More

Model of personalized postprandial glycemic response to food developed for an Israeli cohort predicts responses in Midwestern American individuals.

May 16, 2019

Research paper published in the American Journal of Clinical Nutrition

Read More